First, the caspase-3 activity assay demonstrated that 4-h treatment with NTP-217 did not activate caspase-3 on liver cancer cells, but treatment with NTP-217 for 24 h significantly increased the ratio of cells with activated caspase-3 (Figures 3A, B). Here, CASP3 is linked to liver cancer.